A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb 20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)

Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.